Trial Profile
Induction of HBsAg Decline Using an add-on Treatment of Peginterferon Alfa-2a in HBeAg-negative Chronic Hepatitis B Patients Treated With Nucleos(t)Ide Analogous (PAS)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Adefovir; Entecavir; Tenofovir
- Indications Hepatitis B
- Focus Therapeutic Use
- Acronyms PAS
- 07 Nov 2019 Status changed from active, no longer recruiting to completed.
- 03 Jan 2019 Planned End Date changed from 1 Oct 2019 to 1 May 2020.
- 03 Jan 2019 Planned primary completion date changed from 1 Jun 2019 to 1 Oct 2019.